Pembrolizumab versus placebo as adjuvant therapy in resected high -risk stage II melanoma: Phase 3 KEYNOTE-716 study.

被引：2
|
作者：
Carlino, Matteo S.
Ascierto, Paolo Antonio
Eggermont, Alexander M.
Gershenwald, Jeffrey E.
Grob, Jean Jacques
Hauschild, Axel
Kirkwood, John M.
Long, Georgina V.
Mohr, Peter
Robert, Caroline
Ross, Merrick I.
Scolyer, Richard A.
Sondak, Vernon K.
Yoon, Charles
Poklepovic, Andrew Stewart
Rutkowski, Piotr
Anderson, James R.
Ahsan, Sama
Ibrahim, Nageatte
Luke, Jason J.
机构：
[1] Univ Sydney, Westmead Hosp, Sydney, NSW, Australia
[2] Univ Sydney, Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[4] Gustave Roussy Canc Ctr, Paris, France
[5] Univ Paris Saclay, Paris, France
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Aix Marseille Univ, Marseille, France
[8] Univ Hautklin Kiel, Kiel, Germany
[9] Univ Pittsburgh, UPMC Hillman Canc Ctr, Melanoma Program, Pittsburgh, PA USA
[10] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[11] Royal North Shore Hosp, Sydney, NSW, Australia
[12] Mater Hosp, Sydney, NSW, Australia
[13] Elbe Kliniken Buxtehude, Buxtehude, Germany
[14] Gustave Roussy, Villejuif, France
[15] Paris Sud Univ, Villejuif, France
[16] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[17] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[18] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
[20] VCU Massey Canc Ctr, Richmond, VA USA
[21] Maria Sklodowska Curie Inst, Warsaw, Poland
[22] Merck & Co Inc, Kenilworth, NJ USA
[23] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS9596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9596
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
    Eggermont, Alexander M. M.
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Larkin, James
    Puig, Susana
    Ascierto, Paolo A.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Giacomo, Anna Maria Di
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    Lorigan, Paul C.
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
  • [42] Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630
    Chang, Anne Lynne S.
    Daniels, Gregory A.
    Cohen, Ezra E.
    Ge, Joy Yang
    Gumuscu, Burak
    Swaby, Ramona F.
    Geiger, Jessica L.
    CANCER RESEARCH, 2020, 80 (16)
  • [43] The role of interferon alfa-2b adjuvant therapy of high risk resected melanoma stage I & II.
    Economou, GK
    Koletsis, EN
    Filopoulos, E
    PROCEEDINGS EUROSURGERY 2000, 2000, : 141 - 144
  • [44] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
    Eggermont, Alexander M.
    Meshcheryakov, Andrey
    Atkinson, Victoria
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina V.
    Barrow, Catherine
    Di Giacomo, Anna Maria
    Stephens, Rosalie
    Sandhu, Shahneen Kaur
    Kudchadkar, Ragini Reiney
    Ortiz-Romero, Pablo L.
    Svane, Inge Marie
    Van Akkooi, Alexander Christopher Jonathan
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Phase 3 study of pembrolizumab vs placebo as adjuvant therapy for patients with renal cell carcinoma (RCC): KEYNOTE-564 Asia subset
    Park, Se Hoon
    Chang, Yen-Hwa
    Lee, Jae Lyun
    Kitamura, Hiroshi
    Chung, Jinsoo
    Nishimura, Kazuo
    Kato, Minoru
    Kato, Haruaki
    Kimura, Go
    Masumori, Naoya
    Chiu, Kun-Yuan
    Chang, Chao-Hsiang
    Numakura, Kazuyuki
    Chen Chang
    Burgents, Joseph E.
    Willemann-Rogerio, Jaqueline
    Choueiri, Toni
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 63 - 64
  • [46] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
    McArthur, Heather
    Cortes, Javier
    Dent, Rebecca
    O'Shaughnessy, Joyce
    Pusztai, Lajos
    Kuemmel, Sherko
    Foukakis, Theodoros
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Untch, Michael
    Fasching, Peter A.
    Cardoso, Fatima
    Denkert, Carsten
    Zhu, Yalin
    Ding, Yu
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2023, 83 (05)
  • [47] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Bottomley, Andrew
    Coens, Corneel
    Mierzynska, Justyna
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Puig, Susana
    Ascierto, Paolo A.
    Larkin, James
    Lorigan, Paul C.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    LANCET ONCOLOGY, 2021, 22 (05): : 655 - 664
  • [48] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Li, Tao
    Jia, Dong-Dong
    Teng, Li-Song
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341
  • [49] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
    O'Brien, Mary
    Paz-Ares, Luis
    Marreaud, Sandrine
    Dafni, Urania
    Oselin, Kersti
    Havel, Libor
    Esteban, Emilio
    Isla, Dolores
    Martinez-Marti, Alex
    Faehling, Martin
    Tsuboi, Masahiro
    Lee, Jong-Seok
    Nakagawa, Kazuhiko
    Yang, Jing
    Samkari, Ayman
    Keller, Steven M.
    Mauer, Murielle
    Jha, Nitish
    Stahel, Rolf
    Besse, Benjamin
    Peters, Solange
    LANCET ONCOLOGY, 2022, 23 (10): : 1274 - 1286
  • [50] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    Investigational New Drugs, 2020, 38 : 1334 - 1341
12345